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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.06.017Background: Increasing evidence implicates immune response as a contributing
factor in the failure of allograft valve transplants. Increases in panel reactive
antibodies have been identified in human subjects. To correlate these responses with
novel preimplantation processing methods to reduce cellularity, both a relevant
panel reactive antibody assay and a chronic implantation animal model are neces-
sary. We modified a human flow cytometric panel reactive antibody assay for ovine
model use to detect antibody responses to residual antigen-loading decellularized
scaffolds engineered from pulmonary artery tissue.
Methods: A clinical panel reactive antibody assay was modified with anti-sheep
antibodies. Dimethyl sulfoxide cryopreserved (n  4) and decellularized scaffolds
(n  8) fashioned as patches from pulmonary arteries were implanted for study.
Fresh (nonprocessed) tissue implants were used as positive controls (n  2), and
sham-treated animals were used as negative controls (n  2). Baseline, 10-week,
and 20-week blood samples were assayed for panel reactive antibody levels.
Immunohistochemistry with anti–major histocompatibility complex antibodies were
performed on preimplantation scaffolds.
Results: Chronic implants of fresh tissue stimulated strong panel reactive antibody
responses. Classically cryopreserved tissues provoked modest panel reactive anti-
body responses to major histocompatibility complex I antigen and no response to
major histocompatibility complex II antigen. Decellularized tissue scaffolds pro-
voked minimal to no panel reactive antibody responses to either major histocom-
patibility complex I or II antigen. Immunohistochemistry correlated with the panel
reactive antibody results by identifying significant amounts of major histocompat-
ibility complex I and II in fresh tissue, reduced antigen staining in cryopreserved
control tissues, and minimal amounts in decellularized tissues.
Conclusions: These studies with an ovine modified panel reactive antibody assay
confirmed minimal immune allosensitization to transplanted decellularized tissue
patches. Qualifying criteria for putative tissue-engineered scaffolds should include
minimal recipient panel reactive antibody response.
Increasing data have implicated the body’s immune response in the failureof implanted allograft cardiovascular tissues.1-8 This has been most evidentin pediatric cryopreserved allograft valve reconstructions, where valvesundergoing accelerated failure and functional degeneration have been ex-planted and found to have lymphocytic infiltration within the leaflets andconduit wall.9-11 Bioengineering technologies are being used to develop
alternate implantable acellular scaffolds that are nonantigenic and thus potentially
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possible autorecellularization with autologous cells. One
such alternative is decellularized vascular scaffolds fash-
ioned from allograft aortic and pulmonary artery tissue.
Such acellular scaffolds are derived from allograft vascular
tissues that have been processed with detergents and en-
zymes to remove cells and cellular debris, presumably re-
moving the antigens most likely to initiate allosensitization.
However, to demonstrate efficacy, only human circulating
panel reactive antibodies (PRAs) have been measured in
response to clinically implanted tissues. A large-animal
model is necessary to identify allosensitization and the
effects of increased circulating HLA antibodies on im-
planted valvular and vascular tissue function. We have been
able to modify a beaded flow cytometric PRA method to
detect circulating antibodies to major histocompatibility
complex (MHC) antigens in the chronic implantation sheep
model. This is ideal because the chronic implantation sheep
model has been strongly recommended for valvular and
vascular implant tissue testing (ISO 5840:1996 and US
Food and Drug Administration Replacement Heart Valve
Guidance Document: 1994). In this study, cryopreserved
and decellularized tissue scaffolds were implanted in juve-
nile sheep that were then monitored for the production of
circulating HLA antibodies. Immunohistochemistry for
class I and class II MHC antigens was performed on pre-
implantation tissues to correlate the observed PRA re-
sponses with histologically identifiable MHC I and II anti-
gens retained in the putative scaffold test patches.
Materials and Methods
Tissue Acquisition
Ovine hearts were obtained from laboratory-grade sheep (Animal
Technologies, Tyler, Tex). They were shipped in an antibiotic
solution (RPMI 1640 supplemented with polymyxin B). The pul-
monary valves were dissected and stored in an antibiotic solution
(RPMI 1640 supplemented with polymyxin B, cefoxitin, lincomy-
cin, and vancomycin) at 4°C until either cryopreservation or de-
cellularization processing (24  2 hours).
Cryopreservation
Control tissues were cryopreserved after the disinfection process
was completed. The tissues were cryopreserved in RPMI 1640,
10% fetal calf serum, and 10% dimethyl sulfoxide by using a
Cryomed controlled-rate freezer (Thermo Electron Corporation,
Waltham, Mass). The tissues were frozen at 1°C per minute until
they reached 40°C, after which they were subsequently held in
vapor-phase liquid nitrogen (180°c) until implantation.
Decellularization
The decellularization was performed with a unique detergent-
enzyme-water decellularization process developed at LifeNet Tis-
sue Services (US Patent No. 6,432,712). The grafts were placed in
the decell flow-through chamber, and the detergent (N-lauroylsar-
cosinate), Benzonase endonuclease solution, and polymyxin B
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36 hours. After decellularization, the detergent solution was
drained, and sterile water was recirculated through the tissue
chamber and through a bed of hydrophobic and anion exchange
resins (to remove the anionic detergent) for a time equivalent to the
detergent cycle.
Operation
Sixteen juvenile sheep (age range, 6-18 months) were used. All
animals were acclimated for 1 week at the animal care facility.
Animal handling was in accordance with Brown University insti-
tutional guidelines for the use and care of animals, and the insti-
tutional review board approved the experimental procedures. All
studies also conformed to the “Guide for the Care and Use of
Laboratory Animals” (National Institutes of Health publication
No. 85-23, revised 1985). Anesthesia was induced with propofol (2
mg/kg) administered through an intravenous line placed in the leg.
Once intubated, the sheep were transferred to a preparatory table
and sheared. Electrocardiographic and capnographic monitors
were placed. A small incision was made in the left side of the neck
to allow placement of a carotid artery catheter and an internal
jugular triple-lumen catheter for hemodynamic monitoring pur-
poses. The chest was opened through a thoracotomy in the left
fourth intercostal space. The venous cannula was placed in the
right atrium. An arterial cannula was placed in the descending
thoracic aorta. Cardiopulmonary bypass with oxygenation was
initiated. After clamps were placed, surgical defects were created
for implantation sequentially in the aorta and pulmonary artery.
Elliptical patches fashioned from the pulmonary artery conduit
were sutured to the defects with 4-0 polydioxanone sutures. Pos-
itive control tissues known to contain much antigenic cellular
material (fresh, nonprocessed ovine pulmonary valves) were im-
planted in the descending aorta. All animals received postoperative
antibiotics (amoxicillin [INN: amoxicilline], 5 mg/kg twice daily,
and amikacin, 5 mg/kg twice daily) for 2 weeks and buprenorphine
(1 amp twice daily) analgesia for 3 days.
Four animals per group (n  12 total) were implanted with
patches constructed from one of three tested tissue-processing
methods: cryopreservation; fresh decellularization; or cryopreser-
vation followed by decellularization. Patches were placed in the
aortic and pulmonary positions for each animal (n  24 patches).
Two animals in each test category were killed at the 10- and
20-week time periods. Four additional control animals (2 sham-
treated animals and 2 animals receiving fresh antigen-rich valve
implants) were PRA assayed per protocol and killed at 20 weeks
only.
Explantation was performed through the same thoracotomy
incision after drawing a final PRA sample. Patch measurements
were made under physiologic pressures. The animals were killed
for tissue harvest by the administration of phenobarbital (324
mg/mL; 15 mL per 100 lb) administered through peripheral intra-
venous access.
Flow Cytometry
Blood specimens were collected from the jugular veins of the
sheep and allowed to stand for 2 hours. Clots were removed from
tubes, and remaining serum was run through a HiTrap purification
system (Amersham Biosciences, Buckinghamshire, England) and
ary 2005
Ketchedjian et al Evolving Technology
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MHC I and 30 MHC II antigens for 30 minutes in the dark with
continuous gentle shaking. The beads were washed with buffer
solution and centrifuged at 11,500 rpm for 2 minutes. The super-
natant was removed, and the beads were incubated with a rabbit
anti-sheep fluorescein isothiocyanate antibody (Jackson Immuno-
Research, West Grove, Pa) for 30 minutes in the dark with con-
tinuous shaking. The beads were washed with buffer solution and
centrifuged at 11,500 rpm for 2 minutes. Supernatant was re-
moved, and the beads were fixed in 10% formalin and analyzed on
a Becton Dickinson FACS flow cytometer (Becton Dickinson,
Franklin Lakes, NJ). Human positive and negative controls were
used for calibration. FL1 histograms were obtained for all speci-
mens. Results are reported as the percentage of beads fluorescing,
and increases of greater than 10% are considered positive re-
sponses (per One Lambda), as in clinical use.
Histology and Immunohistochemistry
For MHC staining, segments of the pulmonary and arterial walls
containing test scaffold patches were flash-frozen with dry ice.
They were stored at 80°C until sectioning with a cryostat into
8-m sections, fixed with cold acetone, and stored at 20°C until
staining. The slides were incubated in Dako serum free protein
blocking solution (Dako, Carpinteria, Calif) for 15 minutes at
room temperature. After a 5-minute rinse with dH2O, the slides
were placed in primary antibody for 30 minutes. Mouse anti-sheep
MHC I and II (VMRD, Pullman, Wash) were diluted to 1:50 in 0.1
mol/L phosphate buffer with 5% fetal bovine serum. Slides were
incubated with a secondary antibody, biotinylated mouse immu-
noglobulin G (Vector ABC; Vector Labs, Burlingame, Calif), for
30 minutes and then with a Vector diaminobenzidine peroxidase
substrate kit until reaction (5-10 minutes). The slides were rinsed
and stained with Vector hematoxylin for 15 minutes. Slides were
rinsed and dehydrated through a series of alcohols and Citrisolv
(Fisher Scientific, Pittsburgh, Pa) and permanently covered with a
Surgipath Micromount (Surgipath Medical Industries, Richmond,
Ill).
Statistical Analysis
The quantitative data are presented as a percentage of beads (as
recommended for the analogous human assay by One Lambda)
that are fluorescence positive for antibody binding (PRA), as
determined by means of flow cytometry. Because sham control
PRA values approach baseline values soon after the operation, true
increases are identified by subtracting baseline values from mea-
sured explant PRA values. Group means are compared and ana-
lyzed by means of 1-way analysis of variance (ANOVA; Sigma
Stat, version 2.03) and the Student-Newman-Keuls method.
Results
Immunohistochemistry staining with anti-MHC I and II anti-
bodies (VMRD) were performed on samples of all preimplan-
tation tissues. Nonprocessed (fresh) tissue implants demon-
strated intact endothelium on hematoxylin and eosin (H&E)
staining. The endothelium stained strongly for MHC I antigen
(Figure 1). The staining for MHC II antigen was slightly
weaker but still present throughout the tissue (Figure 2). Cryo-
The Journal of Thoracipreserved tissues demonstrated variable endothelial presence
on H&E staining. Although quantitatively less than nonproc-
essed tissues, MHC I and II antigens were identified through-
out cryopreserved control tissues (Figures 3 and 4). Decellu-
larized tissues never demonstrated endothelium or
myofibroblasts on H&E staining (Figures 5 and 6). MHC I and
II staining demonstrated significantly smaller amounts of an-
tigen within the decellularized tissues, which, when present,
appeared to be localized on the adventitial aspect of the decel-
lularized vascular tissues (Figures 7 and 8).
Flow cytometry was performed on the weekly blood spec-
imens of both the positive and negative control animals (those
receiving nonprocessed tissue implants and sham-treated ani-
mals). Results demonstrated increased levels (over baselines)
of circulating PRA in animals receiving nonprocessed implants
(ie, fresh and antigen rich) within 10 weeks. The 2 sham-
treated animals demonstrated a gradual decrease in circulating
PRA levels soon after the operation, with a gradual return
toward baseline values over time (Figure 9, A, graphic depic-
tion of MHC I, and Figure 9, B, graphic depiction of MHC II).
Cryopreserved patches evoked variable levels of PRA re-
sponse. One each of the two 10- and 20-week animals dem-
onstrated a positive response. None of the four 10-week ani-
mals and only one of the four 20-week animals implanted with
decellularized tissues demonstrated any positive PRA in-
creases (Table 1). The reduced PRA response was significant
when comparing decellularized with both cryopreserved and
fresh tissue for MHC I and significant for MHC II when
comparing decellularized and fresh tissue (P  .05, ANOVA
for each comparison).
The decellularized scaffolds healed with minimal inflam-
mation but with fibrous sheath formation and some recel-
lularization with cell migration. The aortic patches healed
with more extensive fibrous sheaths histologically when
compared with patches in the pulmonary circulation, most
likely attributed to increased shear stress. There were no
aneurysms or endocarditis noted in any of the patches.
Discussion
Levels of PRA after the implantation of vascular transplant
tissues have been studied in the pediatric and adult popula-
tions. Although the specific responses have varied among
different studies, the overall trend has demonstrated that
circulating PRA levels increase after tissue implantation as
a result of allosensitization by donor antigens.6,12-14 Studies
have also suggested that the implantation of decellularized
tissues results in a statistically significant reduction of cir-
culating PRA when compared with that seen in cryopre-
served control tissues.15 However, these studies do have
certain limitations. Because human subjects have been the
sole subjects of circulating antibody studies, it has been
difficult to correlate temporal changes in antibody levels to
the histologic status of the tissue (eg, degeneration, inflam-
c and Cardiovascular Surgery ● Volume 129, Number 1 161
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to obtain tissue for histologic evaluation at varying time
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ognition on the latex beads (99% response by means of flow
Figure 9. These graphs demonstrate circulating PRA leve
(day 7), 2 weeks (day 14), and 6 weeks (day 42) in no
(negative control tissue) control animals. Nonprocessed
I (A) and II (B) PRA levels. There were no positive respon
The y-axis shows the percentage of beads fluorescing, in
the tagged antigens (>10% increases over baseline arecytometry). Sham-treated animals (started on cardiopulmo-
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essed fresh (positive control tissue) and sham-treated
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controls. These animals demonstrated strong MHC I and II
circulating PRA responses.
Cryopreserved and decellularized pulmonary artery tis-
sues were then tested and implanted as patch repairs of
defects in both the pulmonary artery and aorta. Levels of
circulating antibody were measured before implantation and
at 10-week and 20-week intervals. Two of the 3 cryopre-
served animals receiving patch implants had positive results
for circulating antibody response. The increases occurred
mainly in the MHC I class. These observations are typical
and similar to those observed in the human population after
the implantation of cryopreserved tissues. Human studies of
MHC I antibody response detected increases about 50% of
the time, and MHC II response occurred 20% to 30% of the
time.16,17 These observations can be attributed to antigen
frequency and location. Endothelial cells are rich in MHC I
antigen, but their presence can vary as a result of the
consequences of cryopreservation and disinfection tech-
niques.18-20 Residual endothelial cells rich in MHC I anti-
gen on cryopreserved tissue grafts can allosensitize the host
and elicit a measurable antibody response more readily than
MHC II antigens located within the tissue matrix. As clin-
ically used, cryopreserved tissues vary unpredictably in
retained antigen-rich cells, which likely partially explains
the variable durability experiences.21
None of the four 10-week animals and only one of the
TABLE 1. PRA values (indicating relative presence or abse
and 20-week animals
PRA values
Baseline
MHC I
Control
Sham 46%
Sham 47%
Fresh 1.0%
Fresh 13%
10-wk studies
Cryopreserved 26.8%
Cryopreserved (mortality) -
Cryopreserved decellularized 28%
Cryopreserved decellularized 43%
Fresh decellularized 21%
Fresh decellularized 29%
20-wk studies
Cryopreserved 15%
Cryopreserved 0.63%
Cryopreserved decellularized 5.0%
Cryopreserved decellularized 4.4%
Fresh decellularized 10%
Fresh decellularized 68%
Differences in assay results between implant and explant values of great
per human assay manufacturer recommendations). PRA, Panel reactive afour 20-week animals with decellularized patches demon-
164 The Journal of Thoracic and Cardiovascular Surgery ● Janustrated a positive PRA antibody response. The one positive
response was to MHC I class antigen. The response was also
considerably less than its cryopreserved control counterpart.
Similar to human studies, there was a measurable and sta-
tistically significant difference in circulating PRA levels
when comparing decellularized with cryopreserved tissue
(P  .05, ANOVA).
Immunohistochemistry was performed on samples of all
preimplantation tissues to validate the circulating antibody
response measurements. The immunohistochemistry tar-
geted MHC I and II antigens. As expected, nonprocessed
tissue specimens with histologically intact endothelium ex-
pressed large amounts of both MHC I and II antigen, which
also provoked the greatest increase in MHC I and II circu-
lating antibodies, as demonstrated by flow cytometry. Cryo-
preserved tissue patches demonstrated both varying levels
of retained endothelial cellularity and subsequent MHC I
PRA responses. Decellularized tissue scaffolds (whether
preceded by classic cryopreservation or not) demonstrated
the smallest detectable amounts of MHC I and II antigen
and also provoked little or no PRA response.
In modifying the beaded system, certain differences be-
tween the human and sheep models become apparent. Sheep
demonstrated increased resting baseline of MHC I values.
The most likely factor appears to be bacterial (nonspecific
binding from higher levels of circulating immunoglobulin G
generated toward gut flora), which is consistent with known
of recipient MHC I and II antibodies) for control, 10-week,
Baseline
MHC II
Explant
MHC I
Explant
MHC II
0.20% 34% 0.11%
0.19% 32% 0.10%
1.21% 82.3% 53.9%
0.24% 53% 32.3%
34% 48% 0.27%
- - -
0.27% 34% 0.27%
1.15% 51% 10%
40% 27% 0.12%
0.11% 13% 0.13%
1.3% 3.4% 0.12%
0.40% 98% 0.48%
0.63% 41% 2.1%
0.14% 13.5% 0.33%
0.10% 6.6% 0.94%
0.09% 39.6% 0.09%
n 10% are considered positive for circulating panel reactive antibody (as
y; MHC, major histocompatibility complex.nce
er thahigh levels of gastrointestinal flora in ruminants. Increased
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antibiotics. The MHC I measured values, however, drift
back toward the higher baseline values over time once the
antibiotics have been stopped. This problem can be cor-
rected by gating the human negative control to 99.7%. The
threshold for positive responses was defined as 10% over
baseline (as recommended by the human test manufacturer)
to minimize type 1 error. Small increases in PRA levels
soon after implantation might be difficult to identify after
increased baseline values. Lagging time-dependent return to
baseline, however, appears to identify tissue-specific PRA
responses when measured over a longer time period. Such
increased baseline values have also been noted in human
subjects and are inherent to the nonspecific binding prop-
erties of the beads. Antibiotic administration throughout the
chronic phase of the experiment is a potential, although it is
a costly option and risks interfering with the bacterial com-
ponent of ruminant food digestion. It is also critical to
analyze individual animal baselines with each time-interval
specimen. MHC II PRA measurements did not demonstrate
this nonspecific binding phenomenon.
Although the PRA response was positive for nonproc-
essed implants, there was a measurable difference between
them. This might be attributed to the fact that the nonproc-
essed valves were harvested from different animals within
our own laboratory, and in doing so, certain HLA similar-
ities might have existed between the donor and the recipient.
Although ordered at different times, all sheep were obtained
from the same supplier, who maintains a herd of laboratory-
grade sheep, and thus inbreeding could have led to more
similar genotypes.
Understanding the correlation between allosensitization,
HLA incompatibility, and tissue degeneration will be criti-
cal for qualifying tissue-engineered constructs that purport
to avoid the consequences of recipient immune responses.
Our modified ovine method for detecting circulating anti-
body seems to replicate the results seen in human trials.
Such a chronic animal model will be useful in the evaluation
of new bioengineering technologies on the basis of biologic
products that might retain antigenic proteins. Successfully
decellularized scaffolds avoid allosensitization because vir-
tually no MHC antigens are retained. Incomplete decellu-
larization with an excess of cellular debris, however, can
provoke significant immune-mediated inflammation, result-
ing in functional failure.21 If residual cytokines remain in
the extracellular matrix after detergent-enzyme decellular-
ization (which always results in cell necrosis), they can
potentially promote nonspecific inflammatory responses
during reperfusion, even in the absence of retained intact
cells, exacerbating the scar and foreign-body healing re-
sponses, which in turn might promote immune responses
and ultimate failure of the tissue-engineered construct.
MHC immunohistochemistry staining identifies not only
The Journal of Thoraciantigenic intact cells but also residual cellular debris. Dem-
onstrations of acellularity with routine staining methods,
absence of retained donor DNA in preimplantation samples,
or both, are insufficient evidence of adequate reduction of
antigenicity by putative decellularization methods.
PRA titers have been traditionally used in the evaluation
of transplant recipients because the method assays a gener-
alized humoral response that has been useful in the predic-
tion of chronic cell-mediated rejection when activated clin-
ically (regardless of the specific antigen). Cryopreserved
valve transplants seem to fail as a consequence of delayed
or long-term cell-mediated chronic rejection. This pro-
longed failure mode time course is likely the result of lower
levels of antigen when compared with those seen in viable
solid-organ transplants. However, an early detectable hu-
moral response might be identified and used to predict
ultimate T cell– and B cell–mediated pathways of rejection.
Thus, despite the generalized or lumped character of the
panel of reactive antibodies as a test, this very characteristic
specificity has made it sensitive and useful for predicting
long-term tolerance for specific transplanted tissues. Tissue-
engineered constructs, whether derived within or outside of
species, need to be tested for such immunogenic potential.
Thus, in this context preclinical animal chronic implant
evaluations of bioengineered cardiovascular constructs,
such as decellularized allograft scaffolds, should include
documentation of the time course of PRA responses to
correlate preimplantation treatments with potential allosen-
sitization and its effects on ultimate performance, durability,
and even explant morphologic analysis of inflammation,
cell repopulation, and tissue healing. This should aid in
determining whether a putative scaffold design has actually
been adequately biologically decellularized before being
recellularized with phenotypically appropriate cells that will
regenerate normal tissue structure and function or whether
the scaffold material risks provoking immune responses (as
differentiated from nonspecific foreign-body responses),
leading to donor structural protein destruction with inflam-
mation, followed by fibroblast scar formation. Such a se-
quence will lead to functional deterioration, loss of durabil-
ity, and performance characteristics and is a prototypical
failure mode exemplified by the variable clinical experience
with homograft valves, which must be avoided to achieve
the promise of tissue-engineered valves and arteries.
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